For investors, this means the GLP-1 space isnt a trade on a single company anymore its an ecosystem, with value distributed across innovators, generic challengers, CDMO manufacturers, API suppliers, device makers, and the distribution infrastructure connecting all of them
[26] [27] When starting GLP-1 treatment, many patients experience a significant reduction in appetite and early satietyfeeling full after consuming smaller portions
NAD+ supplements, conversely, are thought to influence cellular metabolism through pathways involving sirtuins and other NAD+-dependent enzymes
semaglutide and liraglutide are FDA-approved to treat obesity and are often prescribed alongside lifestyle changes, such as dietary adjustments and increased physical activity